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Summary
Today, molecular-proﬁle-directed therapy is a guiding principle of modern thoracic oncology. The knowledge of new biomolecular tech-
nology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic
surgeons’ professional competence. The European Society of Thoracic Surgeons (ESTS) Biology Club aims at providing a comprehensive
insight into the basic biology of the diseases we are treating. During the 2013 ESTS Annual Meeting, different experts of the ﬁeld presented
the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well
as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.
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INTRODUCTION
Surgical practice is characterized by the continuous improvement
of existing methods as well as the establishment of new techni-
ques. To keep up with this ever changing and evolving ﬁeld of our
specialty, we are forced to constantly expand our knowledge. But
studying takes time and is a difﬁcult process to incorporate into
the busy every day schedule with our commitment to patients’
care.
So the aim of the Biology Club of the European Society of
Thoracic Surgeons is to give a comprehensive insight into the basic
biology of the diseases we are treating in addition to providing an
overview of recent developments/techniques within the ﬁeld. With
a deeper understanding we might be able to bring the clinical
problem from bedside to bench—a mission that cannot be accom-
plished by the pure scientist. This input is important for research,
because the relevant problems are identiﬁed at the bedside. For
many of these so-called translational projects between bench and
bedside, tissue is the key factor, which is provided by the surgeon.
The present article will provide an insight into various technologies
available for the different analyses to be performed and is a
summary of a compact session of the ‘Biology Club’ during the
2013 Annual Meeting of the Society in Birmingham.
Although tumour molecular-proﬁle-directed therapy is already
guiding treatment for lung cancer patients, this is not presently
the case for malignant pleural mesothelioma (MPM), but hopeful-
ly may be one day. In the ﬁrst part of this article, perspectives for
biomolecular diagnosis and prognosis in MPM are addressed and
in the second part modern technologies that have brought new
insights into the molecular basis of lung cancer will be summar-
ized by experts in the ﬁeld.
MESOTHELIOMA: NEW PERSPECTIVES
FOR BIOMOLECULAR DIAGNOSIS
MPM has become an ever increasing model for biomarker discov-
ery as evidenced by a doubling of yearly papers devoted to prog-
nostic, diagnostic and predictive markers since 2000. It only
makes sense to have this tumour as a research priority because of
(i) the socioeconomic burden worldwide which is associated with
asbestos exposure (AE), (ii) a ready-to-study high-risk population
(AE) in many countries, (iii) the very short interval for maturation
of intermediate end points for prognostic biomarker discovery
and (iv) justiﬁcation that there are long-term survivors with MPM
and these long-term survivors are associated with early stage, epi-
thelial histology, female sex and low volumes of disease when
diagnosed. Armed with this information, experts in the MPM re-
search ﬁeld focus on developing minimally invasive, i.e. plasma-
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or serum-based biomarkers, which can then detect the presence
of a mesothelioma in the AE population who exhibits objective AE
[1]. You cannot screen the over 4 million people in the USA who
may have been exposed to asbestos; however, if there was a
serum/plasma test that documented speciﬁcally revealed substan-
tial AE was present, it would be in these individuals that longitu-
dinal screening trials could be explored.
Jube et al. [2] have published that high-mobility group protein 1
(HMGB1), a damage-associated molecular pattern molecule that
triggers the inﬂammatory response that characterizes programmed
necrosis, is elevated in the serum of patients who have documen-
ted exposure to asbestos. These levels of HMGB1 are threefold
higher than in individuals who were not exposed or who are
present or former smokers. Levels of HMGB1, however, are also
elevated in the serum of patients with MPM. Whether HMGB1 is
an early marker of carcinogenesis in AE individuals remains a
primary focus of the investigation of the Yang/Carbone Laboratory
in Hawaii [2, 3], and in the near future a wealth of data deﬁning the
characteristics of those individuals which mitigate this rise in
HMGB1, and a possible forthcoming topic of research is MPM pre-
vention by the use of chemo-preventive agents against HMGB1.
Since HMGB1 is present in the serum of both AE and MPM, it
will not serve as an early detection marker speciﬁc to MPM, since
not all patients with elevated HMGB1 have MPM. Hence, the dis-
covery and validation of novel serum- and plasma-based biomar-
kers has been a primary focus of the Early Detection Research
Network (EDRN) Mesothelioma Biomarker Discovery Laboratory
at New York University Langone Medical Center. After the
groundbreaking work by Robinson et al. [4], describing the use of
soluble mesothelioma-related protein (SMRP) for the diagnosis of
MPM from AE in the Wittenoon Cohort of Western Australia, our
laboratory along with Robinson performed a blinded SMRP valid-
ation of 817 AE vs 168 MPMs (manuscript in preparation, Harvey
Pass). This trial, with the SMRP measured blindly at two separate
laboratories, validated the area under (AUC) the received operat-
ing characteristic curve (ROC) of 0.80 not only in the entire cohort,
but also in patients with Stage I or II disease. Subsequently,
Hollevoet et al. [5] published an individual patient data
meta-analysis of 1026 MPMs and 3465 controls based on data
from 16 studies in the literature, and further conﬁrmed an AUC of
0.80. SMRP, indeed, is a robust marker with good speciﬁcity, but
its sensitivity has so far limited its application for early detection of
MPM in high-risk longitudinally based studies. An EDRN spon-
sored assessment of the Beta-Carotene and Retinol Efﬁcacy Trial
(CARET) study in which 49 cases of MPM were diagnosed from
3897 AE individuals who contributed sera for the chemopreven-
tion study revealed that the ROC of these 49 could generate an
AUC of 0.72 1 year prior to the diagnosis using prediagnostic sera
from these patients (manuscript in preparation, Harvey Pass).
When the SMRP comparisons were performed any longer than 1
year prior to diagnosis, the ability to detect the disease was unsat-
isfactory.
The EDRN laboratory has used genomic technologies to deﬁne
differences between matched pairs of mesothelium (normal peri-
toneum) and MPM from patients having cytoreduction for the
disease. By using Affymetrix™ arrays with over 32 000 probes, a
hierarchy of potentially robust extracellular secreted moieties has
been studied and validated (or not validated!) using enzyme
linked immunosorbent assays (ELISAs). A consistent but controver-
sial molecule, osteopontin (OPN), has always shown signiﬁcant
fold increases in MPM compared with the control mesotheliums,
with 9-fold elevations (P < 2 × 10−13). Indeed, the original
manuscript described remarkable AUCs close to 0.90 for serum
compared with AE and OPN increased in the AE population as a
function of the appearance of the ﬁbrosis, plaque or inﬁltrates on
the computerized tomogram [1]. Unfortunately, it was learnt that
OPN is not speciﬁc to MPM and also the inability to reproduce
the results from the original paper was due to the fact that a
thrombin cleavage molecule impacted on the levels of OPN mea-
sured when performed in serum [6–8] and that OPN ELISAs dif-
fered in reliability [9]. Subsequent investigators conﬁrmed these
ﬁndings by measuring OPN in plasma from MPMs and control
populations with a rise in the AUC to levels comparable with
SMRP [10–12].
Other markers including ﬁbronectin and thrombospondin have
been examined in the New York laboratory, but the most promising
seems to be a member of the Fibulin family, Fibulin 3 (FBLN3),
whose gene is epidermal growth factor receptor (EGF)-containing
ﬁbulin-like extracellular matrix protein 1 (EFEMP1) [13]. In the avail-
able literature, FBLN3 was found to be decreased in tumours com-
pared with normal tissue while in MPM we found that it was 7-fold
increased (P = 10−9) compared with normal mesothelium. Our
ﬁnding of upregulation was validated in silico by examining FBLN3
on expression arrays from Gordon et al. [14] and we then assembled
cohorts of plasmas to examine FBLN3 using a commercially avail-
able ELISA including 142 MPMs, 136 AE, 43 healthy controls, 20
with ovarian cancer, 20 with breast cancer, 20 with glioblastoma
and 31 with prostate cancer. Using MPM cohorts from Detroit and
New York, the AUC for FBLN3 compared with any controls was
consistently >0.95, and maintained 94% speciﬁcity at 100% sensitiv-
ity for Stage I or II lung cancers. Levels of FIBLN3 fell after successful
cytoreduction and increased at the time of progression. A blinded
validation using 48 MPMs and 96 AE from the Princess Margaret
Cancer Center maintained an excellent AUC of 0.87. Moreover,
pleural effusion FBLN3 was markedly elevated and speciﬁc to MPM
effusions compared with benign effusions and effusions from other
cancer histologies. Validation of these ﬁndings from other inter-
national sites is the next most pressing issue using either plasma in a
prospective longitudinal trial or retrospective, longitudinally col-
lected plasmas from high-risk AE.
Industry-related biomarkers for the diagnosis of MPM are also
in validation trials, and the most promising of these is the
SomaLogic 13 marker proﬁle [15]. Using Somamers which are
speciﬁcally designed short pieces of nucleic acids which bind se-
lectively and speciﬁcally to individual proteins, a series of experi-
ments comparing 79 MPMs with 80 AEs in a series of discovery
and blinded validation sets led to the 13 marker algorithm which,
like FBLN3, had consistently elevated AUCs above 0.95 in the dis-
covery and validation sets. Moreover, in a blinded independent
set of 38 MPMs and 62 AEs, an AUC of 0.95 was maintained.
Individual SomaMer predicted proteins have been validated using
commercially available ELISAs, and in a head-to-head comparison
with SMRP with identical specimens, the Somalogic proﬁle had
much greater sensitivity and speciﬁcity. Further validation using
serum from cohorts of other malignancies compared with MPM
using the 13 marker panel is ongoing.
MESOTHELIOMA: NEW PERSPECTIVES
FOR BIOMOLECULAR PROGNOSIS
Developing prognostic markers to decide whether to operate in
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help with aggressive therapy those patients who are likely to
beneﬁt from surgery and to avoid operating on patients who are
unlikely to beneﬁt. This is particularly true in the case of meso-
thelioma where surgery is associated with major morbidity and
ﬁnite mortality, and even patients who recover well do experience
pain and prolonged recovery. Multiple prognostic markers in add-
ition to stage have been previously proposed for mesothelioma
and include laboratory exams (platelet count, haemoglobin and
white blood cell counts), tumour volume (as measured by com-
puted tomography (CT)), histological subtype (epithelial vs
non-epithelial) and lymph node status (as measured by position
emission tomography-CT or preferably mediastinoscopy) [16].
Many of these markers can be obtained prior to deﬁnitive treat-
ment and one should consider utilizing them in the decision-
making process as to who is a reasonable surgical candidate. The
Bueno lab has developed a molecular prognostic test based on
gene expression. This prognostic test is determined by the geo-
metric combination of three ratios of four genes [17]. It has been
developed using microarray analysis and has been validated in 3
retrospective cohorts as well as in 1 prospective cohort of 160
patients who underwent extrapleural pneumonectomy or pleur-
ectomy/decortication. This test remains signiﬁcant in a multivari-
ate model which includes all the other known prognostic tests,
leading the Bueno lab to propose a prognostic score that com-
bines the molecular test with tumour volume, histological subtype
and lymph node status, an approach that has recently been vali-
dated in an independent specimen cohort. While this test has
been developed in frozen tumour tissue, it has recently been con-
verted successfully to a formaldehyde ﬁxed-parafﬁn embedded
tissue-based test. This test has been commercialized and should
be available by early 2014.
Experience with other prognostic tests indicates that the add-
ition of tests from orthogonal platforms can add accuracy. With
the advent of new genomic platforms and technologies, it is
expected that additional such tests may be added to the prognos-
tic test to increase its accuracy. However, as additional groups
explore new tests, it is important to point out that rigorous valid-
ation in sufﬁciently robust independent cohorts including all cur-
rently known prognostic variables be carried out prior to adding
these tests to the clinical armamentarium.
LUNG CANCER: THE ROLE OF MICRORNAS
MicroRNAs (miRNAs) are 19–25-nucleotide-long non-coding
RNAs that regulate gene expression by binding complementary
sequences of target mRNAs and inducing their degradation or
translational repression. Strongly conserved among distantly related
organisms, miRNAs are involved in a variety of biological processes
including cell cycle regulation, differentiation, development, me-
tabolism, neuronal patterning and aging [18]. Alterations in miRNA
expression are involved in the initiation, progression and metastasis
of several human tumours, including lung cancers [19].
Many studies have demonstrated the critical role of miRNAs
in lung cancer pathogenesis and their potential as biomarkers
for lung cancer risk stratiﬁcation, outcome prediction and clas-
siﬁcation of histological subtypes. In 2004, the ﬁrst report was
published showing the potential clinical and biological effects
of such an miRNA alteration in lung cancer. The authors found
that let-7 expression, which regulates kirsten rat sarcoma viral
oncogene homolog, was reduced in lung cancer tissues and
was also associated with shorter survival after surgical resection
[20]. Reintroduction of let-7 has been shown to functionally
inhibit non-small-cell lung tumour development in mouse
models [21].
In addition to lung cancer epithelial tissue, stromal components
could also be an appealing source of early biomarkers, since they
are likely to be affected by carcinogen exposure and strong in-
ﬂammatory conditions such as by chronic obstructive disease.
These are for aggressive lung cancer. Recently, a strong prognostic
gene-expression signature, validated in independent datasets, was
derived from cancer-associated ﬁbroblasts isolated from 15
non-small-cell lung carcinoma samples compared with matched
normal ﬁbroblasts [22]. Another group showed that miRNA ex-
pression proﬁles associated with aggressiveness of the disease and
poor survival were found not only in lung tumours, but also in ad-
jacent normal lung tissue of the tested patients [23]. All these ﬁnd-
ings strengthen the hypothesis of the existence of a lung
microenvironment, likely smoke-related, conducive to tumour
growth.
miRNAs derived from the cancerous tissue or from the tumour
microenvironment could also constitute a new class of blood-
based biomarkers useful for cancer detection and prognosis def-
inition, since, for their nature, they seem to remain rather intact
and stable [24]. Development of non-invasive blood-based bio-
markers for cancer detection in its preclinical phases is crucial to
improve the outcome of deadly diseases such as lung cancer.
Initial studies in lung cancer patients showed that plasma or
serum levels of speciﬁc miRNAs had remarkable sensitivity and
speciﬁcity to distinguish cancer from healthy subjects.
Reasoning that ideal miRNA biomarkers should be identiﬁed
before the onset of the tumours and be able to predict aggressive
vs indolent disease development, it has been found that ratios
among 24 miRNAs were able to discriminate samples collected at
disease or up to 2 years before the disease detection from indivi-
duals enrolled in two independent low-dose computed tomog-
raphy (LDCT) screening trials. Moreover, speciﬁc signatures could
identify correctly subjects who will develop aggressive lung cancer
[23]. In particular, some miRNAs were more important in predis-
ease than in diagnostic signatures and vice versa. This might be
explained by the consideration that genes and pathways necessary
in the earlier phases of disease development are different from
those required for tumour maintenance and progression. Analysing
the performance of these signatures in samples collected predis-
ease, at the time of disease detection and post-surgery, the repro-
ducibility of plasma miRNA test between the predisease and
disease samples was observed (manuscript in preparation, Ugo
Pastorino). In addition, positivity to miRNA signatures fell to nega-
tive after surgery in the majority of subjects, thus conﬁrming the
speciﬁcity of the plasma miRNA assay.
These preliminary data have been recently validated in combin-
ation with LDCT in a larger series composed of more than 1000
individuals enrolled in the Multicentre Italian Lung Detection trial
[25]. Although LDCT is currently the standard of care for early lung
cancer detection [26], it results in a general over diagnosis of indo-
lent nodules, thus increasing individual radiation exposure,
harmful conﬁrmatory diagnostic procedures, unnecessary surgery,
overload of highly specialized medical centres and increased costs
for the healthcare system [27]. Non-invasive circulating miRNA
assays could overcome most of these problems by exploiting the
synergy between the molecular and imaging tests to reduce the
number of the false positives.
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LUNG CANCER: POTENTIAL CLINICAL
APPLICATIONS OF GENOMIC SEQUENCING
There have been considerable advances since the discovery of the
human genome in 2004 [28] and while ‘genomics’ is sometimes
used as a loose term for cancer genetics in general, it applies to
methods that involve DNA sequencing. There have been many
advances in cell biology and genetics that are relevant to the thor-
acic surgeons including disorders of the genome (EGFR receptor
mutations), the transcriptome (mRNA and miRNA diagnostic and
prognostic proﬁling), the proteome (melanoma antigen family A, 3
expression for immunotherapeutics) and in future the metabolome
(products of cell metabolism). In this section, we focus on gene se-
quencing of DNA.
DNA sequencing technology continues to improve, with an ex-
ponential increase in output per instrument run between 2004
and 2006 [29], and the costs and time required continues to drop
signiﬁcantly [30]. Currently, there are different scales to which the
genome can be sequenced, at the level of the whole genome,
whole exome and targeted sequencing. Whole genome sequen-
cing includes both intron (coding regions of the DNA) and exons
(non-coding regions of the DNA). This is the complete DNA se-
quence and the information yield is often unwieldy requiring spe-
cialized bioinformatics input for interpretation. This can now be
achieved with Next-Generation Sequencers; however, the output
is so large that it is difﬁcult to interpret and suitable only for re-
search at this stage. The next level is whole exome sequencing,
which reveals the coding region of the DNA and currently a lot of
biology and exploratory work is being undertaken at this level to
help understand carcinogenesis, cancer biology and the search for
new drug targets [31].
Currently, the level that is most applicable is targeted sequen-
cing, which covers only the DNA regions of interest. This can be
achieved by a number of different techniques ranging from
Next-Generation Sequencing to simple polymerase chain reac-
tion. In clinical practice, these techniques have been used in re-
search on diagnosis, prognosis and treatment predictions.
Plasma quantiﬁcation of DNA in lung cancer has been under-
taken by Sozzi et al. [32] in an attempt to develop a blood-based
marker for lung cancer diagnosis with promising results in the devel-
opment cohort with an ROCAUC of 0.94 (0.91–0.97); however, the
level of discrimination dropped in a further validation cohort to
conclude that plasma DNA was not different in individuals who
developed CT-detected lung cancers vs cancer-free control subjects
and was only slightly higher at the time of cancer diagnosis [33].
There is no doubt that among the most important discoveries
in today’s management of lung cancer is the presence of drug
treatable mutations (EGFR and anaplastic lymphoma kinase)
leading to considerable improvement in lung cancer survival [34–
36]. In the surgical setting, randomized double-blind trial in adju-
vant NSCLC with tarceva is a study of adjuvant erotinib in post-
surgical patients with EGFR drug sensitizing mutations and we are
currently awaiting the results. Perhaps one of the most interesting
and relevant uses of DNA mutation testing in surgery is the setting
of preoperative induction treatment. Researchers in Toronto re-
cently published an abstract on the outcomes of preoperative
erlotinib in 22 patients reporting evidence of radiographic regres-
sion of tumours [37] opening the door for the consideration of tar-
geted induction treatment.
Other recent advances include blood-based DNA mutation
testing, and we and others have published on the ability to
capture circulating tumour cells [38] with the potential of DNA ex-
traction and mutation testing.
In summary, genome sequencing can now be undertaken with
greater output, higher speed and lower costs. While whole
genome and exome sequencing are currently research techni-
ques, targeted sequencing is already being applied in clinical prac-
tice. Improvements to genome sequencing may guide research
surgical practice through adjuvant treatment, induction treat-
ments and future minimally invasive methods of lung cancer diag-
nosis. All this emphasizes the importance of surgeon participation
in tissue banking and basic translational research.
CONCLUSION
The appreciation of concepts such as multiclonality, genomic sig-
natures and epigenetics represents the foundation of translational
medicine in thoracic oncology [39–42]. The clinical implications of
this triad are potentially manifold and only partially understood at
this point in time [43, 44]. In this setting, thoracic surgeons are not
simply spectators of this new era but rather main actors with their
clinical acumen, surgical skills and central role in the diagnostic
and therapeutic pathways of lung cancer and mesothelioma [40,
45, 46]. The ever evolving knowledge of the most frequent genetic
mutations and their signiﬁcance either as predictors of drug re-
sponse or as prognosticators represents a fundamental part of the
modern thoracic surgical practice [40, 46–48]. Moreover, new per-
spectives are disclosing that will require further reshaping the pro-
fessional proﬁle of thoracic surgeons who will increasingly rely on
additional diagnostic capabilities in the selection of surgical candi-
dates [49, 50]. Indeed, multidisciplinary involvement in thoracic
oncology cannot thrive without this knowledge, which is an essen-
tial ‘Esperanto’ of lung cancer and mesothelioma tumour boards
in an effort to improve the quality of service to our patients [51].
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